Development and optimization of solid self-nanoemulsifying drug delivery system (S-SNEDDS) using Scheffe's design for improvement of oral bioavailability of nelfinavir mesylate

Drug Delivery and Translational Research

Volumn 4, Issue 2, 2014, Pages 171-186

  Patel, Archita ^a   Shelat, Pragna ^a   Lalwani, Anita ^a  

^a K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Nelfinavir mesylate; Neusilin US2; Scheffe's mixture design; Solid self nanoemulsifying drug delivery system

Indexed keywords

CREMOPHOR; LABRASOL; MAISINE 35 1; NELFINAVIR; OIL; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG SOLUBILITY; EX VIVO STUDY; IN VIVO STUDY; INTESTINE FLUID; NANOEMULSION; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; STOMACH JUICE; X RAY DIFFRACTION;

EID: 84897432199     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-014-0191-1     Document Type: Article

References (47)

1. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother. 2001;45: 1086-93. doi: 10. 1128/AAC. 45. 4. 1086-1093.
2. Yihong Q. Developing solid oral dosage forms: pharmaceutical theory and practice. New York: Elsevier; 2009.
3. PRVIRACEPT (2011) http://www. pfizer. ca/en/our_products/products/monograph/133. Accessed 2 July 2013.
4. Patick AK, Mo H, Markowitz M, Appelt K, Wu B, Kalish V, et al. Antiviral and resistance studies of ag1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996;40: 292-7.
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharmacol. 2004;1: 85-96. doi: 10. 1021/mp034006h.
6. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Del Rev. 1999;39: 211-38. doi: 10. 1016/S0169-409X(99)00027-7.
7. 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol. 2005;45: 1198-205. doi: 10. 1177/0091270005280051.
8. Torne SJ, Torne JS, Vavia PR, Singh SK. Inclusion complexes of anti-hiv drug with β-Cyclodextrin. Chemistry and materials science. J Inc Pheno Macro Chem. 2006;56: 253-59. doi: 10. 1007/S10847-006-9092-3.
9. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Rev. 1997;25: 47-58. doi: 10. 1016/S0169-409X(96)00490-5.
10. Kale A, Patravale VB. Design and evaluation of self-emulsifying drug delivery system (SEDDS) of nimodipine. AAPS PharmSciTech. 2008;9(1): 191-6. doi: 10. 1208/s12249-008-9037-9.
11. Shaji J, Jadhav D. Newer approaches to self emulsifying drug delivery system. Int J Pharm Pharm Sci. 2010;2: 37-42.
12. Hauss D. Oral lipid-based formulations. Adv Drug Del Rev. 2007;59: 667-7. doi: 10. 1016/j. addr. 2007. 05. 006.
13. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 2004;278: 119-31. doi: 10. 1016/j. ijphrm. 2004. 03. 001.
14. Wandel C, Kim RB, Stein CM. "Inactive" excipients such as cremophor can affect in vivo drug disposition. Clin Pharmacol Ther. 2003;73: 394-96. doi: 10. 1016/S0009-9236(03)00010-9.
15. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 1998;87: 164-69. doi: 10. 1021/js970300n.
16. Rege B, Kao J, Polli J. Effect of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16: 237-46. doi: 10. 1016/S0928-0987(02)00055-6.
17. Elnaggar YSR, El-Massik MA, Abdallah OY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm. 2009;380: 133-41. doi: 10. 1016/j. ijpharm. 2009. 07. 015.
18. Gupta S, Chavhan S, Sawant K. Self-nanoemulsifying drug delivery system for adefovir dipivoxil: design, characterization, in vitro and ex vivo evaluation. Colloids and Surfaces A: Physicochem Eng Aspects. 2011;392: 145-55. doi: 10. 1016/j. colsurfa. 2011. 09. 048.
19. Oh DH, Kang JH, Kim DW, Lee BJ, Kim JO, Yong CS, et al. Comparison of solid selfmicroemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Int J Pharm. 2011;28: 412-18. doi: 10. 1016/j. ijpharm. 2011. 09. 007.
20. Paola M, Maurizio V, Marzia C, Natascia M. New solid self microemulsifying systems to enhance dissolution rate of poorly water soluble drugs. Pharm Dev Technol. 2012;17: 277-84. doi: 10. 3109/10837450. 2010. 535825.
21. Dong WK, Jun HK, Dong HO, Han-Gon C. Development of novel flurbiprofen-loaded solid self-microemulsifying drug delivery system using gelatin as solid carrier. J Microencapsul. 2012;29: 323-30. doi: 10. 3109/02652048. 2011. 651497.
22. Kang JH, Oh DH, Oh YK, Yong CS, Choi HG. Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS). Eur J Pharm Biopharm. 2012;80: 289-97. doi: 10. 1016/j. ejpb. 2011. 11. 005.
23. Venkata RK, Suresh B, Raju J, Prabhakar RV. Oral self emulsifying powder of lercanidipine hydrochloride: formulation and evaluation. Powder Tech. 2012;221: 375-82. doi: 10. 1016/j. powtec. 2012. 01. 032.
24. Shanmugam S, Baskaran R, Balakrishnan P, Thapa P, Yong CS, Yoo BK. Solid self nanoemulsifying drug delivery system (S-SNEDDS) containing phosphatidylcholine for enhanced bioavailability of highly lipophilic bioactive carotenoid lutein. Eur J Pharm Biopharm. 2011;79: 250-7. doi: 10. 1016/j. ejpb. 2011. 04. 012.
25. Saipin S, Sirima M, Narubodee P, et al. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm. 2010;76: 475-85. doi: 10. 1016/j. ejpb. 2010. 07. 011.
26. Janolya A, Bleyzaca N, Favettab P, Gagneuc M, Aulagner G. Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma. J Chromatogr B. 2002;780: 155-60. doi: 10. 1016/S1570-0232(02)00465-8.
27. Scheffe H. Experiments with mixtures. J Royal Stat Soc Ser B. 1958;20: 344-60.
28. Colas JC, Shi W, Rao VSNM, Omri A, Mozafari MR, Singh H, et al. Microscopical investigations of nisin-loaded nanoliposomes prepared by Mozafari method and their bacterial targeting. Micron. 2007;38: 841-47. doi: 10. 1016/j. micron. 2007. 06. 013.
29. Bandivadekar M, Pancholi S, Kaul-Ghanekar R, Choudhari A, Koppikar S. Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study. Drug Dev Ind Pharm. 2013;39: 696-703. doi: 10. 3109/03639045. 2012. 687745.
30. Bhagwat DA, D'Souza JI, Intru J. Bhagwat J and D'souza Formulation and evaluation of solid self micro emulsifying drug delivery system using aerosil 200 as solid carrier. International Current Pharmaceutical Journal. 2012;1: 414-19.
31. Chen Y, Chen C, Zheng J, Chen Z, Shi Q, Liu H. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull. 2011;34: 278-86.
32. Sarwar B, Jeena SS, Patra NC, Rizwan M, Swaina S, Sruti J, et al. Development of solid self-nanoemulsifying granules (SSNEGs) of ondansetron hydrochloride with enhanced bioavailability potential. Colloids Surf B: Biointerfaces. 2013;101: 414-23. doi: 10. 1016/j. colsurfb. 2012. 06. 031.
33. Smith P. Methods for evaluating intestinal permeability and metabolism in vitro. Pharm Biotechnol. 1996;8: 13-34. doi: 10. 1007/978-1-4899-1863-5-2.
34. BorhadeV SS, Patravale V. Clotrimazole nanoemulsion for malaria chemotherapy. Part I: Preformulation studies, formulation design and physicochemical evaluation. Int J Pharm. 2012;431: 138-48. doi: 10. 1016/j. ijpharm. 2011. 12. 040.
35. Rangel-Yagui CO, Junior AP, Tavares LC. Micellar solubilization of drugs. J Pharm Pharm Sci. 2005;8: 147-63.
36. Fuzheng R, Yanhui T, Yongjia S, Xinhong Y, Zhian H. Determination of nelfinavir mesylate as bulk drug and in pharmaceutical dosage form by stability indicating HPLC. J Pharm Biomed Anal. 2006;41: 1065-69. doi: 10. 1016/j. jpba. 2006. 02. 003.
37. Barot BS, Parejiya PB, Patel HK, Gohel MC, Shelat PK. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: optimization of formulation using D-Optimal design. AAPS PharmSciTech. 2012;13: 184-92. doi: 10. 1208/s12249-011-9742-7.
38. Ren S, Mu H, Alcher F, Chtatou A, Mullrtyz A. Optimization of self nanoemulsifying drug delivery system for poorly water-soluble drug using response surface methodology. Drug Dev Ind Pharm. 2013;39(5): 799-806. doi: 10. 3109/03639045. 2012. 710634.
39. Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech. 2010;11: 314-21. doi: 10. 1208/s12249-010-9385-0.
40. Tharwat F. Applied surfactants: principles and applications. Weinheim: Wiley-VCH; 2005.
41. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000;50: 179-88. doi: 10. 1016/S0939-6411(00)00089-8.
42. Parul S, Ranjana M, Bakhshib AK. Stress degradation studies of nelfinavir mesylate by Fourier transform infrared spectroscopy. J Pharm Biomed Anal. 2010;53: 287-94. doi: 10. 1016/j. jpba. 2010. 03. 030.
43. Aulton ME. Aulton's pharmaceutics: the design and manufacture of medicines. 3rd ed. Hungary: Harcourt; 2007.
44. Martin HA, Wantanee P, Navnit HS, Zhang Lin; Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate. United States patent US7014866. 14 Nov 2002.
45. Sha X, Yan G, Yunjuan W. Junchan Li and Fang X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci. 2005;24: 477-86.
46. Nerukar MM, Burton PS, Bourchart RT. The use of surfactants to enhance permeability of peptides through Caco-2 cells by inhibition of an apically polarized system. Pharm Res. 1996;13: 528-34. 10. 1023/A: 1016033702220.
47. Beg S, Swain S, Singh HP, Patra CN, Rao MB. Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech 2012;13: 1416-27.